{"id":"tolvaptan-torasemide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypernatremia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Thirst"},{"rate":null,"effect":"Polyuria"}]},"_chembl":{"chemblId":"CHEMBL344159","moleculeType":"Small molecule","molecularWeight":"448.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination leverages two complementary diuretic mechanisms: tolvaptan is an aquaretic that selectively increases free water clearance without significant electrolyte loss, while torasemide is a loop diuretic that increases overall fluid excretion. Together, they provide enhanced diuresis for conditions requiring aggressive fluid management, such as decompensated heart failure or cirrhotic ascites, with potentially better electrolyte balance than loop diuretics alone.","oneSentence":"Tolvaptan blocks vasopressin V2 receptors to promote water excretion, while torasemide inhibits the Na-K-Cl cotransporter in the loop of Henle to increase sodium and water loss.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:13:03.298Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Decompensated heart failure with fluid overload"},{"name":"Cirrhotic ascites and edema"}]},"trialDetails":[{"nctId":"NCT02644616","phase":"PHASE4","title":"The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement","status":"COMPLETED","sponsor":"Shanghai Chest Hospital","startDate":"2014-11","conditions":"Tricuspid Regurgitation, Right Heart Failure","enrollment":40},{"nctId":"NCT01663662","phase":"PHASE4","title":"The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study","status":"WITHDRAWN","sponsor":"University of Michigan","startDate":"2012-08","conditions":"Heart Failure","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"tolvaptan+torasemide","genericName":"tolvaptan+torasemide","companyName":"Shanghai Chest Hospital","companyId":"shanghai-chest-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tolvaptan, a vasopressin V2 receptor antagonist, is used in combination with torasemide for the treatment of heart failure, including right heart failure and tricuspid regurgitation. The combination of tolvaptan and torasemide has been studied in clinical trials for its safety and efficacy in these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}